Partnering to Accelerate What Matters
Our collaborative agreements with leading pharmaceutical and biotechnology companies are central to our mission of advancing impactful therapies for patients. These collaborations take various forms — ranging from strategic alliances and joint ventures to licensing agreements — depending on what best serves patient needs. By aligning with top biopharmaceutical companies and strategic investors, we integrate the unique infrastructure and drug development capabilities of Therapeutics Discovery with the innovative therapeutics and expertise of our collaborators to accelerate the delivery of new treatments. Through joint ventures, we establish new companies to advance promising medicines discovered by our teams, leveraging the managerial, operational and investment strengths of our partners. Additionally, we license novel therapeutics developed within our platforms to companies committed to progressing these medicines through development and early-stage clinical trials.
Strategic Industry Ventures
Our team works closely with UT MD Anderson’s Office of Strategic Industry Ventures (SIV) to cultivate meaningful, long-term relationships with companies that share UT MD Anderson's vision for transforming cancer care. The SIV team plays a pivotal role in supporting our pharmaceutical alliances and facilitating seamless collaborations with biotech innovators, accelerating the development of cutting-edge cancer therapeutics and bringing them closer to the patients who need them most.
Strategic Collaborations
Our collaborations with leading biopharmaceutical companies and strategic investors enable us to bring innovative medicines to our patients quickly, safely and effectively.
-
Artios
In-licensing agreement by Artios of small-molecule ATR inhibitor program developed by Discovery and ShangPharma
-
Boehringer Ingelheim
Collaboration to accelerate development of therapies targeting the MAPK, TRAILR2 and other pathways
-
C-Biomex
Collaborative research agreement to co-develop CBT-001 radioligand therapy
-
Crossbow
Development of antibody that targets HLA-A02-restricted peptides displayed on cell surface after Cathepsin G processing
-
CTMC
Joint venture launched with National Resilience, Inc. to accelerate development and manufacturing of cell therapies
-
CureVac
Co-development and licensing agreement to develop mRNA-based cancer vaccines
-
Eisbach Bio
Strategic collaboration to develop medicines targeting DNA binding proteins in oncology
-
Generate:Biomedicines
Co-development agreement to accelerate development of protein therapies using generative AI
-
Nexo Therapeutics
Strategic collaboration to rapidly advance cancer therapies against previously undruggable targets
-
Recursion (Previously Exscientia)
Collaboration to leverage AI in developing novel small molecule oncology therapies
-
Taiho Oncology
Collaboration to conduct preclinical development and clinical evaluation of novel medicines
Give Now
Research Areas
Find out about the four types of research taking place at UT MD Anderson.